Angiodynamic Inc (NASDAQ:ANGO)’s traded shares stood at 0.55 million during the last session, with the company’s beta value hitting 0.58. At the close of trading, the stock’s price was $12.43, to imply a decrease of -2.66% or -$0.34 in intraday trading. The ANGO share’s 52-week high remains $13.13, putting it -5.63% down since that peak but still an impressive 57.68% since price per share fell to its 52-week low of $5.26. The company has a valuation of $502.99M, with an average of 1.3 million shares in intraday trading volume over the past 10 days and average of 641.76K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Angiodynamic Inc (ANGO), translating to a mean rating of 1.00. Of 3 analyst(s) looking at the stock, 0 analyst(s) give ANGO a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.13.
Angiodynamic Inc (NASDAQ:ANGO) trade information
After registering a -2.66% downside in the last session, Angiodynamic Inc (ANGO) has traded red over the past five days. The 5-day price performance for the stock is 1.06%, and 33.23% over 30 days. With these gigs, the year-to-date price performance is 35.70%. Short interest in Angiodynamic Inc (NASDAQ:ANGO) saw shorts transact 1.0 million shares and set a 1.8 days time to cover.
The extremes give us $12 and $14 for target low and target high price respectively. As such, ANGO has been trading -12.63% off suggested target high and 3.46% from its likely low.
Angiodynamic Inc (ANGO) estimates and forecasts
Looking at statistics comparing Angiodynamic Inc share performance against respective industry, we note that the company has underperformed competitors. Angiodynamic Inc (ANGO) shares are 78.85% up over the last 6 months, with its year-to-date growth rate lower than industry average at 0.00% against 15.00%. The rating firms project that company’s revenue will shrink -6.25% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is 70.3M. Meanwhile, for the current quarter, a total of 3 analyst(s) estimate revenue growth to 74.23M.Earnings reports from the last fiscal year show that sales brought in 65.97M and 70.98M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 6.56% before jumping 4.58% in the following quarter.
ANGO Dividends
Angiodynamic Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Angiodynamic Inc (NASDAQ:ANGO)’s Major holders
Angiodynamic Inc insiders hold 5.60% of total outstanding shares, with institutional holders owning 81.30% of the shares at 86.13% float percentage. In total, 81.30% institutions holds shares in the company, led by BLACKROCK INC.. As of 2024-06-30, the company held over 4.6 million shares (or 11.4443% of shares), all amounting to roughly $27.86 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 2.19 million shares, or about 5.4418% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $13.25 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Angiodynamic Inc (ANGO) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 1.2 shares. This is just over 2.96% of the total shares, with a market valuation of $14.9 million. Data from the same date shows that the other fund manager holds a little less at 985.55, or 2.44% of the shares, all valued at about 12.25 million.
